

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – September 14, 2016 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Keast

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. July 13, 2016 DUR Minutes – Vote
B. July 13, 2016 DUR Recommendations Memorandum
C. August 10, 2016 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Action Item – Update on Medication Coverage Authorization Unit/Concomitant Benzodiazepine and Opioid Utilization – See Appendix B

- A. Medication Coverage Activity for August 2016
B. Pharmacy Help Desk Activity for August 2016
C. Concomitant Benzodiazepine and Opioid Utilization

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Dexilant™ SoluTab (Dexlansoprazole Delayed-Release Orally Disintegrating Tablets) – See Appendix C

- A. Indication(s) and Dosing
B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize AK-Tracin® (Bacitracin) and Bleph-10® (Sulfacetamide Sodium) Ophthalmic Ointment – See Appendix D

- A. Indication(s)
B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Betoptic® (Betaxolol Ophthalmic Solution), Timoptic-XE® (Timolol Maleate Ophthalmic Gel-Forming Solution), & Betimol® (Timolol Ophthalmic Solution) – See Appendix E

- A. Introduction
B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Nasarel® (Flunisolide Nasal Spray) – See Appendix F

- A. Introduction
B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Ocaliva™ (Obeticholic Acid) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Belbuca™ (Buprenorphine Buccal Film), Dolophine® (Methadone), MorphaBond™ (Morphine Extended-Release), Xtampza™ ER (Oxycodone Extended-Release), & Probuphine® (Buprenorphine Implant) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Vivlodex™ (Meloxicam Capsules) – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. Annual Review of Prednisolone Special Formulations and 30-Day Notice to Prior Authorize Millipred™ (Prednisolone Sodium Phosphate Oral Solution 10mg/5mL) – See Appendix J

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Prednisolone Special Formulations
- D. Prior Authorization of Prednisolone Special Formulations
- E. Prednisolone Special Formulations Claims Analysis
- F. Millipred™ (Prednisolone Sodium Phosphate Oral Solution 10mg/5mL) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Prednisolone Special Formulations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

13. Annual Review of Synagis® (Palivizumab) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Palivizumab
- C. Prior Authorization of Palivizumab
- D. Season Comparison
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

14. Action Item – Annual Review of Antihyperlipidemics – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Antihyperlipidemics
- C. Prior Authorization of Antihyperlipidemics
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Statin Medications and Zetia® (Ezetimibe)
- G. Utilization Details of Omega-3 Fatty Acids
- H. Utilization Details of Juxtapid® (Lomitapide) and Kynamro® (Mipomersen)
- I. Utilization Details of PCSK9 Inhibitors

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

15. Action Item – Annual Review of Anticoagulants and Platelet Aggregation Inhibitors – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
- D. Market News and Updates
- E. College of Pharmacy Recommendations

- F. Utilization Details of Anticoagulants
- G. Utilization Details of Platelet Aggregation Inhibitors

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

16. Annual Review of Dry Eye Disease Products and 30-Day Notice to Prior Authorize Xiidra™ (Lifitegrast 5% Ophthalmic Solution) – See Appendix N

- A. Utilization of Dry Eye Disease Products
- B. Dry Eye Disease
- C. Xiidra™ (Lifitegrast Ophthalmic Solution) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

17. Annual Review of Butalbital Products and 30-Day Notice to Prior Authorize Allzital® (Butalbital/Acetaminophen 25mg/325mg) & Esgic® Capsules (Butalbital/Acetaminophen/Caffeine 50mg/325mg/40mg) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of Butalbital Products
- C. Prior Authorization of Butalbital Products
- D. Pricing Trend(s)
- E. Allzital® (Butalbital/Acetaminophen 25mg/325mg) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Butalbital Products

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

18. FDA and DEA Updates – See Appendix P

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

- A. Heart Failure Medications
- B. Targeted Immunomodulator Agents
- C. Breast Cancer Medications
- D. Skin Cancer Medications
- E. Constipation and Diarrhea Medications
- F. Topical Corticosteroids
- G. Bladder Control Medications
- H. Topical Lidocaine Medications
- I. Growth Hormone

**Future business subject to change.*

20. Adjournment